We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
FDA Commissioner Scott Gottlieb announced his resignation on Tuesday and said he will leave the agency in about a month, just under two years from his appointment in May 2017. Read More
Drugmaker and pharmacist groups called on the FDA to amend its draft guidance on supply chain verification systems, saying the draft doesn’t account for the varying conditions at facilities. Read More
FDA Commissioner Scott Gottlieb highlighted the agency’s plans to expand data collection on adverse event reporting in his Feb. 27 testimony before a key House appropriations subcommittee. Read More
Petitions aimed at delaying approvals of competing drugs are diverting resources away from the agency’s public health efforts, the FDA said in a report to Congress. Read More
The UK laid out proposed changes to bring needed sunlight to clinical trials in a policy report released by recently appointed Under Secretary of State for Health, Nicola Blackwood. Read More
As pressure continues to build on drugmakers to address high drug prices, Eli Lilly announced that it will market a half-priced generic of its Humalog insulin injection in the U.S. Read More
Novartis filed a lawsuit on Friday accusing Janssen of falsely claiming that its plaque psoriasis drug Tremfya (guselkumab) is superior to Novartis’ product, Cosentyx (secukinumab). Read More
The FDA required a clinical trial among rheumatoid arthritis patients to test the risk of heart problems, cancer and opportunistic infections. Read More